معرفی
Dr. Max Crüsemann is a researcher at the Institut für Pharmazeutische Biologie, part of the Rheinische Friedrich-Wilhelms-Universität Bonn. His research focuses on the discovery and biosynthesis of natural products, particularly antibiotics and G protein inhibitors. Utilizing advanced bioinformatics and -omics methodologies, his group aims to accelerate the identification of bioactive compounds and engineer their biosynthetic pathways for therapeutic applications.
Key research areas include understanding the enzymology of natural product biosynthesis, exploring structural diversity in microbial metabolites, and investigating ecological functions of these compounds. His work bridges microbiology, chemistry, and pharmacology, with a focus on drug development and sustainable solutions for antibiotic resistance.
Notable contributions include studies on the FR900359 Gq signaling inhibitor and its biosynthetic pathway, as well as the discovery of novel antibiotics like Hypeptin. His publications highlight interdisciplinary approaches to natural product genomics, metabolomics, and synthetic biology.
Collaborations span global institutions, emphasizing open science initiatives like MIBiG 4.0 and molecular networking for metabolite discovery. His lab actively engages in translational research, targeting applications in medicine and environmental sustainability.
